Medical therapies for chronic menorrhagia

Obstetrical and Gynecological Survey

Volumn 62, Issue 4, 2007, Pages 272-281

  Nelson, Anita L ^a,c   Teal, Stephanie B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DANAZOL; DESMOPRESSIN; DICLOFENAC; FLUFENAMIC ACID; FLURBIPROFEN; GESTAGEN; GONADORELIN AGONIST; IBUPROFEN; INDOMETACIN; IRON; LEVONORGESTREL; MECLOFENAMATE SODIUM; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; TRANEXAMIC ACID; TRICHLOROACETIC ACID;

CHRONIC DISEASE; CLINICAL TRIAL; DRUG MECHANISM; EMERGENCY PATIENT; ENDOMETRIUM ABLATION; FAMILY; HUMAN; MENORRHAGIA; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; SOCIAL INTERACTION; UTERUS BLEEDING; VAGINAL HYSTERECTOMY; WORK;

ANDROGENS; ANTIFIBRINOLYTIC AGENTS; CHRONIC DISEASE; CONTRACEPTIVES, ORAL, COMBINED; CYCLOOXYGENASE INHIBITORS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IRON; MENORRHAGIA; PROGESTINS; TRICHLOROACETIC ACID;

EID: 34147107416     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000259228.70277.6f     Document Type: Review

References (80)

1. Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update 2002;8:60-67.
2. Côté I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 2002;100:683-687.
3. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 1998:CD001016.
4. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss - a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320-351.
5. Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 2004;190:1224-1229.
6. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. Obstet Gynecol 2001;98:806-814.
7. Fraser IS, McCarron G, Markham R, et al. Blood and total fluid content of menstrual discharge. Obstet Gynecol 1985;65:194-198.
8. Chimbira TH, Anderson AB, Turnbull A. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. BJOG 1980;87:603-609.
9. Haynes PJ, Hodgson H, Anderson AB, et al. Measurement of menstrual blood loss in patients complaining of menorrhagia. BJOG 1977;84:763-768.
10. Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol 2004;190:1216-1223.
11. Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006;20:511-521.
12. Philipp CS, Faiz A, Dowling N, et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005;105:61-66.
13. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-459.
14. Edlund M, Blomback M, von Schoultz B, et al. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996;53:234-238.
15. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998;351:485-489.
16. Gregerman RI. Thyroid disorders. In: Barker LR, Burton JR, Zieve PD, eds. Principles of Ambulatory Medicine. 4th ed. Baltimore: Williams & Wilkins, 1995:1036.
17. Siegel JE. Abnormalities of hemostasis and abnormal uterine bleeding. Clin Obstet Gynecol 2005;48:284-294.
18. Crofton MD. Clinical management of abnormal uterine bleeding. APGO educational series on women's health issue. Association of Professors of Gynecology and Obstetrics, May 2002. Available at: http://www.apgo.org/ bookstore/index.cfm?docid=000C539E-2809-1D0A-A715A5EFD804B4F2. Accessed Apr 7, 2005.
19. Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol 1996;175:787-792.
20. Dawood MY. Nonsteroidal antiinflammatory drugs and reproduction. Am J Obstet Gynecol 1993;169:1255-1265.
21. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 1998:CD000400.
22. Vargyas JM, Campeau JD, Mishell DR Jr. Treatment of menorrhagia with meclofenamate sodium. Am J Obstet Gynecol 1987;157:944-950.
23. Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998;104(3A):30S-34S.
24. Edwards JE, Moore RA, McQuay HJ. Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data. BMC Womens Health 2004;4:5.
25. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-2073.
26. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. BJOG 1989;96:840-844.
27. Cameron IT, Leask R, Kelly RW, et al. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 1987;34:99-110.
28. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879-883.
29. Gleeson N, Devitt M, Sheppard BL, et al. Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding. Br J Obstet Gynaecol 1993;100:768-771.
30. Bonnar J, Sheppard BL, Dockeray CL. The haemostatic system and dysfunctional uterine bleeding. Res Clin Forums 1983;5:27-36.
31. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003;63:1417-1433.
32. Gleeson NC, Buggy F, Sheppard BL, et al. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73:274-277.
33. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. BJOG 1995;102:401-406.
34. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996;313:579-582.
35. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000:CD000249.
36. Munro MG. Medical management of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000;27:287-304.
37. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993;70:238-240.
38. Awwad JT, Toth TL, Schiff I. Abnormal uterine bleeding in the perimenopause. Int J Fertil Menopausal Stud 1993;38:261-269.
39. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990;30:353-356.
40. Richter HE, Learman LA, Lin F, et al. Medroxyprogesterone acetate treatment of abnormal uterine bleeding: factors predicting satisfaction. Am J Obstet Gynecol 2003;189:37-42.
41. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006:CD003855.
42. Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol 1993;169:1134-1139.
43. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. BJOG 1998;105:592-598.
44. Schwallie PC, Assenzo JR. Contraceptive use - efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973;24:331-339.
45. Cameron IT. The levonorgestrel intrauterine system: the benefits of reduced bleeding. Eur J Contracept Reprod Health Care 2001;6(Suppl 1):27-32.
46. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. BJOG 1990;97:690-694.
47. Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 2003;79:963-969.
48. Tang GW, Lo SS. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception 1995;51:231-235.
49. Lähteenmäki P, Haukkamaa M, Puolakka J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998;316:1122-1126.
50. Monteiro I, Bahamondes L, Diaz J, et al. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. Contraception 2002;65:325-328.
51. Kingman CE, Kadir RA, Lee CA, et al. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004;111:1425-1428.
52. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Syst Rev 2005;CD002126.
53. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005;112:1121-1125.
54. Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol 2004;104:1314-1321.
55. Busfield RA, Farquhar CM, Sowter MC, et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding. BJOG 2006;113:257-263.
56. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456-1463.
57. National Health Committee Working Party. Guidelines for the Management of Heavy Menstrual Bleeding. Available at: http://www.nzgg.org.nz/guidelines/0032/ HMB_fulltext.pdf.Accessed April 7, 2005.
58. Royal College of Obstetricians and Gynecologists. The Management of Menorrhagia in Secondary Care. National Evidence-Based Clinical Guidelines. Available at: http://www.rcog.org.uk/guidelines.asp?PageID=108&GuidelineID= 29. Accessed April 7, 2005.
59. Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;CD000154.
60. Hickey M, Higham J, Fraser IS. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 2000;CD001895.
61. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913-920.
62. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001;285:2347-2354.
63. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002;186:389-395.
64. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96.
65. Stewart FH, Kaunitz AM, Laguardia KD, et al. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol 2005;105:1389-1396.
66. Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 2005;106:473-482.
67. Beaumont H, Augood C, Duckitt K, et al. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2002;CD001017.
68. Munro MG. Abnormal uterine bleeding in the reproductive years. 2. Medical management. J Am Assoc Gynecol Laparosc 2000;7:17-35.
69. Moghissi KS. A clinician's guide to the use of gonadotropin-releasing hormone analogues in women. Medscape Womens Health 2000;5:5.
70. Colacurci N, De Placido G, Mollo A, et al. Short-term use of Goserelin depot in the treatment of dysfunctional uterine bleeding. Clin Exp Obstet Gynecol 1995;22:212-219.
71. Crow J, Gardner RL, McSweeney G, et al. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin. Int J Gynecol Pathol 1995;14:235-242.
72. Oehler MK, Rees MC. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003;82:405-422.
73. Thomas EJ. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids. BJOG 1996;103 (Suppl 14):18-21.
74. Shwayder JM. Pathophysiology of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000;27:219-234.
75. Gerber B, Krause A, Reimer T, et al. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res 2006;12:1245-1250.
76. Bulun SE, Imir G, Utsunomiya H, et al. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol 2005;95:57-62.
77. Shozu M, Murakami K, Inoue M. Aromatase and leiomyoma of the uterus. Semin Reprod Med 2004;22:51-60.
78. Kucuk M, Okman TK. Intrauterine instillation of trichloroacetic acid is effective for the treatment of dysfunctional uterine bleeding. Fertil Steril 2005;83:189-194.
79. Echlin D, Garden AS, Salmon P. Listening to patients with unexplained menstrual symptoms: what do they tell the gynaecologist? BJOG 2002;109:1335-1340.
80. Kennedy AD, Sculpher MJ, Coulter A, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes and costs: a randomized controlled trial. JAMA 2002;288:2701-2708.